In its Q1 2026 earnings call, Getinge AB (GNGBY) reported an organic net sales growth of 0.8% and a 3.9% increase in order intake, reflecting solid business performance despite facing significant challenges. The company recorded an adjusted gross profit of SEK3,828 million and an adjusted EBITDA of SEK824 million, although this was adversely affected by currency and tariff impacts totaling SEK226 million. Getinge's financial health remains robust, with free cash flow reaching SEK842 million and a net debt of SEK9.3 billion, adjusted to SEK7 billion when excluding pension liabilities. Notably, recurring revenue now accounts for two-thirds of sales, indicating a strategic shift towards high-margin products. However, the Acute Care Therapies segment experienced a decline in order intake due to high comparative figures from the previous year. The company did not provide specific margin guidance for 2026 due to ongoing global uncertainties, particularly geopolitical risks in the Middle East. The launch of the Cardiohelp II, which has received CE approval, is expected to bolster Getinge's leadership in Extracorporeal Life Support (ECLS) therapy.